Journal of Probiotics & Health
Open Access
ISSN: 2329-8901
ISSN: 2329-8901
Gregory Leyer
Accepted Abstracts: J Prob Health
Metabolic syndrome is a growing epidemic, not only in western cultures but in developing nations as well. The economic toll of the various components that make up metabolic syndrome is staggering. The role of the microbiota is being demonstrated in many applications that can result in phenotype transfer, and improvement in physiological function. This talk will discuss metabolic syndrome, and the latest developments in the roles of active ingredients, specifically Probiotics, on metabolic syndrome and specifically the impact on Type 2 diabetes.
Gregory Leyer received his Ph.D. from the University of Wisconsin-Madison in the Department of Food Microbiology and Toxicology where he studied various food-borne pathogens. He began his post-graduate career at Abbott Nutrition (Columbus, OH) in Medical Nutritional Product Development where for five years he focused on probiotic applications for pediatric and adult specific needs. He has been with DuPont-Danisco for 14 years, holding various R&D Director, Innovation Manager, and Global Business Development Director positions for 14years.